Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ninerafaxstat - Imbria Pharmaceuticals

Next Previous
Drug Profile

Ninerafaxstat - Imbria Pharmaceuticals

Alternative Names: IMB-101 - Imbria pharmaceticals; IMB-1018792; IMB-1018972; IMB-1018972 trihydrochloride monohydrate; IMB101

Latest Information Update: 04 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Imbria Pharmaceuticals
  • Class Antiarrhythmics; Carboxylic acids; Cardiovascular therapies; Heart failure therapies; Piperazines; Pyridines; Small molecules; Vasodilators
  • Mechanism of Action Partial fatty acid oxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Angina pectoris; Diabetic cardiomyopathy; Hypertrophic cardiomyopathy
  • Preclinical Heart failure
  • No development reported Myocardial ischaemia

Most Recent Events

  • 19 Jun 2025 Imbria Pharmaceuticals plans the phase IIb FORTITUDE-HCM trial in Hypertrophic cardiomyopathy (PO, Tablet) in July 2025 (NCT07023614)
  • 29 Mar 2025 Efficacy result from phase II clinical trial in Diabetic cardiomyopathy released by Imbria
  • 31 Dec 2024 Imbria Pharmaceuticals plans a phase III trial for Hypertrophic cardiomyopathy in 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top